Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Kidney (renal cell) cancer
Stage/Subtype:  recurrent renal cell cancer
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 61 for your search:
Start Over
Radiosurgery in Treating Patients With Kidney Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CASE12806, P30CA043703, NCI-2010-01064, NCT00458484
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110013, 11-C-0013, NCT01218867
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: N1153, NCCTG-N1153, CDR0000720022, NCI-2012-00095, U10CA031946, NCT01497444
Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 07811, NCT01510119
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: I146308, NCI-2009-01599, NCT01582009
A Phase 1/2 Study to Evaluate MEDI4736
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CD-ON-MEDI4736-1108, NCT01693562
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 105RC101, NCT01806064
Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: NHLBI
Protocol IDs: CDR0000066610, NHLBI-97-H-0196, NCT00003553
BMS 247550 to Treat Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 020130, 02-C-0130, NCI-02-C-0130, CC-02-C-0130, NCI-3654, 3654, NCT00033670, NCT00030992
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 2001LS058, UMN-MT2001-10, 0108M06725, UMN-2001LS058, NCT00303719
Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: 080088, 08-C-0088, NCT00923845
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 100114, 10-C-0114, NCT01130519
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000681614, ECOG-E1808, E1808, NCT01164228
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 100166, 10-C-0166, NCT01174121
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 78,256, NCT01237457
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-226, NCT01399918
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01289, CDR0000738785, PHII-122, 9048, N01CM00038, P30CA033572, NCT01664182
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MC1152, NCI-2012-02027, Mod11-003340-15, Mod11-003340-20, P30CA015083, NCT01767636
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 140037, 14-C-0037, NCT02019693
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IRB00072091, NCI-2014-02112, WINSHIP2645-14, NCT02273752
Natural Killer Cells and Bortezomib to Treat Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NHLBI
Protocol IDs: 080186, 08-H-0186, NCT00720785
Dose-escalation Study of Oral CX-4945
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C4-08-001, NCT00891280
An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-166, NCT01184326
Study of Everolimus (RAD001)in Combination With Lenalidomide
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IRB00031088, WCI1717-09, NCT01218555
Start Over